Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
22 May 2012
|
| In: |
Leukemia and lymphoma
Year: 2012, Jahrgang: 53, Heft: 11, Pages: 2290-2292 |
| ISSN: | 1029-2403 |
| DOI: | 10.3109/10428194.2012.682311 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.3109/10428194.2012.682311 Verlag, Volltext: https://doi.org/10.3109/10428194.2012.682311 
|
| Verfasserangaben: | Eva Walter, Thomas Schmitt, Sascha Dietrich, Anthony Ho, Mathias Witzens-Harig |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1587563495 | ||
| 003 | DE-627 | ||
| 005 | 20220815102232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190212s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/10428194.2012.682311 |2 doi | |
| 035 | |a (DE-627)1587563495 | ||
| 035 | |a (DE-576)517563495 | ||
| 035 | |a (DE-599)BSZ517563495 | ||
| 035 | |a (OCoLC)1341037788 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Walter, Eva |e VerfasserIn |0 (DE-588)1177819309 |0 (DE-627)1048924688 |0 (DE-576)517563010 |4 aut | |
| 245 | 1 | 0 | |a Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy |c Eva Walter, Thomas Schmitt, Sascha Dietrich, Anthony Ho, Mathias Witzens-Harig |
| 264 | 1 | |c 22 May 2012 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.02.2019 | ||
| 700 | 1 | |a Schmitt, Thomas |d 1980- |e VerfasserIn |0 (DE-588)13302928X |0 (DE-627)530941902 |0 (DE-576)265846404 |4 aut | |
| 700 | 1 | |a Dietrich, Sascha |d 1979- |e VerfasserIn |0 (DE-588)136406300 |0 (DE-627)694354635 |0 (DE-576)301003408 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Witzens-Harig, Mathias |e VerfasserIn |0 (DE-588)1050736516 |0 (DE-627)784812322 |0 (DE-576)404988970 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 53(2012), 11, Seite 2290-2292 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy |
| 773 | 1 | 8 | |g volume:53 |g year:2012 |g number:11 |g pages:2290-2292 |g extent:3 |a Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3109/10428194.2012.682311 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.3109/10428194.2012.682311 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190212 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 1050736516 |a Witzens-Harig, Mathias |m 1050736516:Witzens-Harig, Mathias |d 910000 |d 910100 |e 910000PW1050736516 |e 910100PW1050736516 |k 0/910000/ |k 1/910000/910100/ |p 5 |y j | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 136406300 |a Dietrich, Sascha |m 136406300:Dietrich, Sascha |d 910000 |d 910100 |e 910000PD136406300 |e 910100PD136406300 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 13302928X |a Schmitt, Thomas |m 13302928X:Schmitt, Thomas |d 910000 |d 910100 |e 910000PS13302928X |e 910100PS13302928X |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1177819309 |a Walter, Eva |m 1177819309:Walter, Eva |d 910000 |d 910100 |e 910000PW1177819309 |e 910100PW1177819309 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1587563495 |e 305574568X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"id":{"eki":["324746237"],"zdb":["2030637-4"],"issn":["1029-2403"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapyLeukemia and lymphoma","note":["Gesehen am 08.09.15"],"origin":[{"publisherPlace":"London [u.a.] ; London [u.a.]","dateIssuedKey":"1989","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedDisp":"1989-"}],"recId":"324746237","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Leukemia and lymphoma","title_sort":"Leukemia and lymphoma"}],"part":{"year":"2012","text":"53(2012), 11, Seite 2290-2292","volume":"53","pages":"2290-2292","extent":"3","issue":"11"},"language":["eng"],"pubHistory":["1.1989/90 -"]}],"note":["Gesehen am 12.02.2019"],"physDesc":[{"extent":"3 S."}],"id":{"doi":["10.3109/10428194.2012.682311"],"eki":["1587563495"]},"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"22 May 2012"}],"recId":"1587563495","type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"display":"Walter, Eva","role":"aut","given":"Eva","family":"Walter"},{"role":"aut","given":"Thomas","display":"Schmitt, Thomas","family":"Schmitt"},{"display":"Dietrich, Sascha","role":"aut","given":"Sascha","family":"Dietrich"},{"given":"Anthony Dick","role":"aut","display":"Ho, Anthony Dick","family":"Ho"},{"family":"Witzens-Harig","display":"Witzens-Harig, Mathias","given":"Mathias","role":"aut"}],"name":{"displayForm":["Eva Walter, Thomas Schmitt, Sascha Dietrich, Anthony Ho, Mathias Witzens-Harig"]},"language":["eng"],"title":[{"title_sort":"Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy","title":"Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy"}]} | ||
| SRT | |a WALTEREVASRITUXIMABA2220 | ||